

Freedom of Information Act 2000**The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 09 April 2024****FOI Ref No: 24286****Requested Information:**

I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions.

- 1) How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease

- 2) In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)
 - Hemlibra in combination with any Factor VIII
 - NovoEight
 - NovoSeven RT
 - Nuwiq
 - Obizur
 - Refacto AF
 - Any other products

- 3) For patients treated with Advate in the last three months, please provide:
 - the number of haemophilia A patients treated prophylactically -
 - the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) -

- 4) In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - Factor Eight Inhibitor Bypass Activity (FEIBA)
 - Hemlibra (standalone)

- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Nuwiq
- Obizur
- Refacto AF
- Any other products

Response:

Please note the data we hold and are reporting is from 01/10/23 – 31/12/23, the next 3 months data will be available after 31/04/24.

I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions.

- 1) How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.

- 54 Mild
- 6 Moderate
- 16 Severe

- 2) In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?

- Advate 4
- Adynovi 0
- Elocta 1
- Esperoct 2
- Factor Eight Inhibitor Bypass Activity (FEIBA) 0
- Hemlibra (standalone) 0
- Hemlibra in combination with any Factor VIII 0
- NovoEight 0
- NovoSeven RT 1
- Nuwiq 0
- Obizur 0
- Refacto AF 0
- Any other products 0

3) For patients treated with Advate in the last three months, please provide:

- the number of haemophilia A patients treated prophylactically - 0
- the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) - 5

4) In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- Advate 1
- Adynovi 0
- Elocta 0
- Esperoct 1
- Factor Eight Inhibitor Bypass Activity (FEIBA) 0
- Hemlibra (standalone) 0
- Hemlibra in combination with any Factor VIII 0
- NovoEight 0
- NovoSeven RT 0
- Nuwiq 0
- Obizur 0
- Refacto AF 0
- Any other products 0

Attachment(s):

None

Date Response sent: